Patient Education · Medical Weight Loss
What is retatrutide? The triple agonist, explained
Retatrutide is the most talked-about investigational weight loss medication in the world right now, and most of what patients read about it online is marketing. Here is the honest version from a medical weight loss provider: what it is, what the trials actually showed, and what it means for your options today.
Not FDA approved. Not legal to compound. Not offered by Vesta. This page is educational only.
Please Read First
Vesta Aesthetics does not offer retatrutide.
We do not prescribe, stock, dispense, or waitlist it, and we cannot: retatrutide is not FDA approved, and federal law does not allow any 503A or 503B compounding pharmacy to prepare it. The FDA has issued warning letters to companies selling so-called compounded retatrutide. Outside a clinical trial, anyone offering it to you today is operating outside the law. This page exists so you can understand the science and make safe decisions; the proven, legal options are covered at the bottom.
One injection, three metabolic pathways.
Retatrutide is an investigational once-weekly injectable developed by Eli Lilly. Where semaglutide activates one receptor (GLP-1) and tirzepatide activates two (GLP-1 and GIP), retatrutide activates three: GLP-1, GIP, and glucagon. The glucagon pathway is the newcomer, and it appears to add meaningful energy expenditure on top of the appetite regulation the other two provide. In Phase 3 results reported in 2026, average weight loss reached approximately 28 percent of body weight at 80 weeks at the highest studied doses, the largest figure ever reported for an anti-obesity medication. Eli Lilly has said it plans to file with the FDA by early 2027, so an approval decision, if it comes, would follow that review. Until then, retatrutide is not legally available from any provider or pharmacy, and Vesta does not offer it.
Retatrutide vs tirzepatide vs semaglutide, in one table.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors activated | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| FDA status | Approved | Approved | Investigational; Lilly plans to file with the FDA by early 2027 |
| Reported average weight loss in trials | Roughly 14 to 15 percent over 68 to 72 weeks | Roughly 20 percent over 72 weeks | Roughly 28 percent at 80 weeks (Phase 3, highest doses) |
| Dosing | Once weekly | Once weekly | Once weekly (investigational) |
| Available through a licensed provider today | Yes | Yes | No. Not FDA approved, not legal to compound, and not offered by Vesta |
Trial figures come from different studies with different designs and populations; comparisons are approximate, not head-to-head. Individual results vary. Discuss expectations with a licensed provider.
About the retatrutide already for sale online.
Because the trial results are so striking, an entire gray market has appeared: websites selling retatrutide labeled for research use only, no prescription required. Be careful. These products are unapproved investigational substances. Their purity, dose accuracy, and sterility cannot be verified, and no licensed US pharmacy stands behind them. The FDA has repeatedly warned consumers about unapproved GLP-1 products sold online. Compounded retatrutide is not a legal workaround either: because retatrutide is not FDA approved, has no USP monograph, and is not on the FDA bulk substances lists, no 503A or 503B pharmacy can legally compound it, and the FDA began issuing warning letters to companies selling it in September 2025.
Vesta Aesthetics dispenses prescriptions exclusively through licensed 503A compounding pharmacies, with every protocol prescribed individually by Ali Claunch, NP-C after a personalized clinical evaluation. That standard is exactly why Vesta does not offer retatrutide, and will not until it is FDA approved and legally available. It is also why we publish pages like this one: informed patients make safer decisions, whatever they decide.
Should you wait for retatrutide, or start now?
For most patients, waiting for an approval that is likely still a year or more away rarely beats starting a medically supervised program now. FDA-approved pathways through semaglutide and tirzepatide already deliver substantial, well-studied results, and the metabolic benefits of starting earlier compound over time. Your plan can evolve as new medications are approved; your starting point does not lock you in.
Vesta provides provider-led medical weight loss by telehealth across Utah, Arizona, and Idaho. Care begins with a $75 initial consultation where Ali reviews your goals, history, and labs, then builds a personalized protocol around what is right for you today.
Retatrutide FAQs.
Curious what is right for you, today?
Skip the gray market. A $75 HIPAA compliant telehealth consultation with Ali Claunch, NP-C maps your options across Utah, Arizona, and Idaho.
Explore Medical Weight LossPractice updates & treatment insights
Subscribe for practice updates, announcements, and treatment insights. For Utah, Arizona & Idaho patients, unsubscribe any time.
Deciding between medications? Semaglutide vs tirzepatide, compared →
Your plan starts with a $75 initial consultation
Meet one-on-one with Ali Claunch, NP-C through a HIPAA compliant telehealth consultation. We review your goals, health history, and labs, then build a personalized treatment plan. Caring for patients across Utah, Arizona, and Idaho, with in-clinic visits in Saratoga Springs.
Follow-up visits are included with an active membership. À la carte patients schedule a $75 follow-up consult at least every 90 days while on therapy. Decide on a membership within 7 days of your consultation and the $75 comes straight off your first month.
Schedule a ConsultationA Note on Compounded Medications and FDA Oversight
Compounded peptides, GLP-1 medications, hormone therapies, NAD+ preparations, and other prescription items dispensed through Vesta Aesthetics are prepared by licensed 503A compounding pharmacies for individual patients pursuant to a valid prescription from Ali Claunch, NP-C, following a personalized clinical evaluation. Compounded medications are not FDA-approved. The FDA does not evaluate compounded preparations for safety, efficacy, or potency. Vesta Aesthetics operates in compliance with FDA regulations governing 503A patient-specific compounding and does not stock, hold, or distribute medications; every prescription is compounded for the named patient and shipped by the pharmacy directly to that patient. If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation.
Information on this site is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary by patient. No specific clinical result is promised or guaranteed. Use of any prescription medication carries risk; please review all risks with your provider before beginning therapy. Vesta Aesthetics is a self-pay medical practice and does not bill insurance. See our 503A Promise for full sourcing detail.